Healthcare

CytoDyn (OTC: CYDY) to Hold Investment Community Conference Call on February 6, 2020

VANCOUVER, Washington, Feb. 03, 2020  — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader […]

Healthcare

CytoDyn (OTC: CYDY) Announces Stunning Results from Clinical Trials Evaluating mTNBC and MBC with Leronlimab and will Request an Emergency Type C Meeting with FDA to Enroll 50 Awaiting Patients with a Serious Solid Tumor Cancer Condition

Third patient data supports leronlimab (PRO 140) as a potential treatment option for metastatic triple-negative breast cancer (mTNBC) and metastatic breast cancer (MBC). Patient CTC dropped to zero after 2 weeks of leronlimab treatment, same […]

Newsmakers

NexTech (OTC: NEXCF) Signs Partner Agreement with Jolokia Bringing AR to the Global Learning and Development Industry

AR and Interactive Video combine to create world’s most compelling training platform NEW YORK and TORONTO, Jan. 28, 2020– NexTech AR Solutions (the “Company” or “NexTech”) (otcqb:NEXCF) (NTAR)(N29) NexTech AR Solutions, the industry leader in […]

Healthcare

CytoDyn’s (OTC: CYDY) Leronlimab Under Evaluation for Potential Treatment of Coronavirus

CytoDyn and IncellDX in discussions with potential partners about the use of leronlimab to treat 2019 Novel Coronavirus (2019-nCoV) VANCOUVER, Washington, Jan. 28, 2020  — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology […]

Healthcare

CytoDyn (OTC: CYDY) Abstract by Dr. Jonah Sacha for Use of Leronlimab as PrEP is Accepted by the Keystone Symposia on HIV Pathogenesis and Cure

VANCOUVER, Washington, Jan 27, 2020 — The poster and oral presentation will highlight the role of the CCR5 antibody in preventing macaques from intrarectal Simian-Human Immunodeficiency Virus (SHIV) Based on these strong results, CytoDyn has […]

Healthcare

Impressive Results Continue from CytoDyn’s (OTC: CYDY) Clinical Trials Evaluating Two Patients with Leronlimab, One in mTNBC and One in MBC

VANCOUVER, Washington, Jan 22, 2020 — First patient with metastatic triple-negative breast cancer (mTNBC) continues to show no detectable circulating tumor cells (CTC) or putative metastatic tumor cells after 15 weeks of treatment with leronlimab […]

Healthcare

CytoDyn (OTC: CYDY) Files for Breakthrough Therapy Designation with the FDA for the Use of Leronlimab for the Treatment of Metastatic Triple-Negative Breast Cancer

VANCOUVER, Washington, Jan. 13, 2020  — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the […]

Consumer

Nightfood (OTC: NGTF) Continues Hotel Expansion, Will Exhibit at the Hotel Supply Show of the Southeast

Nightfood sleep-friendly ice cream in hotel freezers can deliver better-for-you snacking benefits to road-weary travelers Tarrytown, NY –  January 06, 2020 – Nightfood, Inc. (OTCQB: NGTF), the award-winning ice cream company addressing America’s $50 billion-dollar […]